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Objective: To study the efficacy and safety of single intravenous bolus administration of
indigenously developed tenecteplase (TNK-tPA) in the management of patients with ST-
elevation myocardial infarction (STEMI) in clinical practice.
Methods: Observational, prescription-event monitoring study.
Results: Data of 15,222 patients who had STEMI and received weight adjusted TNK injection
was analyzed. Overall 95.43% patients had clinically successful thrombolysis (CST). In the
different subgroups, hypertensives, diabetics, smokers and hyperlipidemic patients had
CST rates comparable to the general patient data. CST rates were significantly lower in the
elderly patients (>70 years; 92.11%; p < 0.0001), in patients with history of Ischemic Heart
Disease (IHD, 93.86%; p ¼ 0.0004) and in patients receiving delayed treatment (>6 h after
onset of chest pain; 85.38%; p < 0.0001). CST was significantly higher in patients who
received an early thrombolysis (<3 h after onset of chest pain; 96.54%; p ¼ 0.006). Overall
mortality was 1.69%, while it was significantly higher in the elderly (4.42%), patients with
history of IHD (2.67%), females (2.93%) and in those who received delayed treatment
(4.98%). The overall incidences of intracranial hemorrhage (ICH), bleeding excluding ICH,
stroke and ventricular tachyarrhythmia were 0.39%, 2.01%, 0.16% and 2.35% respectively.
Age >70 years, diabetes, hyperlipidemia and history of IHD were associated with a higher
incidence of heart failure, myocardial re-infarction or ventricular tachyarrhythmias.
However, incidence of ICH and bleeding other than ICH was comparable amongst all pa-
tient subgroups.(S.S. Iyengar).
2013, Cardiological Society of India. All rights reserved.
i n d i a n h e a r t j o u rn a l 6 5 ( 2 0 1 3 ) 4 3 6e4 4 1 437Conclusion: This study confirms the safety and efficacy of indigenous tenecteplase in Indian
patients with STEMI, including high risk subgroups. It also highlights the fact that delayed
treatment denotes denial of benefits of pharmacologic reperfusion therapy.
Copyright ª 2013, Cardiological Society of India. All rights reserved.1. Introduction Subgroups of diabetic, hypertensives, hyperlipidemic,In the current era of interventional cardiology, thrombolysis
in ST-Elevated Myocardial Infarction (STEMI) continues to be
an important life saving modality of reperfusion therapy,
especially in countries like India where Primary PCI is either
not available at all, or is not possible within the time frame of
120min from the first medical contact (FMC) as recommended
in the guidelines.1 Bolus dose treatment with tenecteplase is
expected to give better results than infused thrombolytics like
alteplase, as highlighted in the ACC/AHA guidelines of 2004.2
This article presents the safety and efficacy data from the
post-marketing surveillance registry established for the use of
indigenous tenecteplase (TNK-tPA) in Indian patients with
STEMI. Earlier publications from this registry have highlighted
the efficacy and safety of tenecteplase in high-risk sub groups
of Indian patients with STEMI.32. Materials and methods
2.1. Compilation of data
Data from 15,222 consecutive patients was collected and
analyzed from de-identified case record forms (CRFs) from
1152 cardiologists/physicians across 722 centers across India,
as documented in the Indian Registry for TNK-tPA. Indigenous
tenecteplase, manufactured by Gennova Biopharmaceuticals
Ltd at Pune, India, was administered to patients of STEMI
reporting to the hospitals and centers specified above, in a
weight adjusted dosing pattern at the discretion of the treat-
ing cardiologist/physician. Adjuvant medication was also
administered as per the physician’s instructions. Detailed
information pertaining to the demography of the patients, co-
morbidities, time of onset of chest pain to administration of
tenecteplase injection and all other requisite safety and effi-
cacy data were recorded on Case Report Forms (CRF). The
principal efficacy parameter was a clinically evident success-
ful thrombolysis, as indicated by a significant relief in chest
pain and resolution of the ST-segment elevation on the ECG.
Adverse Events including Intracranial hemorrhage (ICH), non-
ICH bleeding, heart failure, ventricular arrhythmias, myocar-
dial re-infarction, mortality and any other serious adverse
drug reactions (ADR) were the recorded safety parameters.
The study was a non-interventional, observational, prescrip-
tion e event monitoring study in actual clinical practice.
2.2. Statistical analysis
The data was analyzed centrally by medically qualified
personnel not associated with the treatment of the patients.smokers, elderly (age >70 years), females, patients receiving
tenecteplase within 6 h andmore than 6 h after onset of chest
pain and patients with Killip Class III and IV were analyzed
separately for safety and efficacy. Any adjustment of ‘p’ is not
done for multiple comparisons as indicated for any of the
subgroup analyses. However, exact ‘p’ values are reported so
that “Bonferronis’ adjustment” can easily be used by the
reader, if desired.
The statistical tests applied (using GraphPad Instat Version
2.00) were unpaired Student’s t test (for comparing means
with standard deviation) and Chi square test (for comparing
proportions).3. Results
3.1. Demography
Breakup of demographic characteristics of the 15,222 patients
included in the study is shown in Tables 1e3. In brief, it con-
sisted of 61.52% hypertensives, 41.32% diabetics, 33.28%
smokers, 23.54% hyperlipidemics, 18.18% patients with a
history of IHD, 16.83% females and 8.36% elderly patients of
above 70 years age. 5.93% patients received tenecteplase in-
jection>6 h after the onset of chest pain, while almost 66% got
it within 3 h. The percentage of patients with Killip Class III
and IV, who received TNK, was 7.47% and 2.02%, respectively.
46.19% of the patients had anterior wall MI.
3.2. Concomitant medication
Out of the total patients screened, more than 99% received
both clopidogrel and aspirin (99.17% and 99.07%, respectively),
while 95.05% received unfractionated or lowmolecular weight
heparin. Beta blockers and nitroglycerine were administered
in 39.88% and 34.11% patients respectively. Glycoprotein IIb/
IIIa inhibitors (GPI) were administered in 661 (4.34%) patients.
3.3. Efficacy
The overall rate for achieving clinically successful thrombol-
ysis (CST) by TNKwas 95.43%. Success rates were significantly
lower (92.11%) in elderly patients (>70 years) (p < 0.0001) and
in patients with a history of IHD (93.86%) (p ¼ 0.0004). Hyper-
tensives, diabetics, smokers and hyperlipidemics had success
rates corresponding to the overall patient data. It was estab-
lished that delayed administration of TNK (>6 h of onset of
symptoms) gives lower success rates (85.38%; p > 0.0001), as
against those patientswho received TNKwithin 3 h of onset of
symptoms (96.54%) and within 3e6 h (96.07%), which is
Table 1 e Demographic data.
Parameter No of patients e N (%) Age e years (Mean  SD) Weight e kg (Mean  SD) Sex ratio (M:F)
Total 15,222 (100%) 55.41  10.98 69.27  10.58 4.94
Females 2561 (16.82%) 57.54  11.05 65.35  10.58 e
Elderly 1268 (8.33%) 75.67  4.52 69.09  11.99 3.34
Hypertensives 9366 (61.53%) 56.38  10.50 70.20  10.42 4.8
Diabetics 6291 (41.33%) 57.59  10.13 70.24  10.39 4.64
Hyperlipidemics 3584 (23.54%) 57.11  11.20 70.63  10.70 5.08
Smokers 5066 (33.28%) 53.95  11.11 70.71  10.19 25.6
Patients with h/o IHD 2768 (18.18%) 56.87  6.71 70.14  10.21 6.84
Patients treated within 3 ha 10,044 (65.98%) 55.12  10.87 69.01  10.51 5.03
Patients treated within 3e6 ha 4268 (28.304%) 55.92  10.90 70.19  10.58 4.92
Delayed treatment (>6 ha) 903 (5.93%) 56.29  12.77 67.81  11.12 4.27
Killip Class III and IV 1446 (9.50%) 55.15  11.31 70.65  10.20 4.81
IHD e ischemic heart disease.
a Time from onset of chest pain.
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Patients with Killip Class I and II had a CST of 95.76% and
96.44% respectively, whereas those with Killip Class III & IV, it
was 92.97% and 77.92% respectively, which is significantly
lower than the general population (p > 0.0001). Female pa-
tients (94.69%) had a CST comparable with the male patients
(95.57%) ( p ¼ 0.53) (Figs. 1 and 4).
Patients with anterior wall MI had lower success rates
(80.45% vs 95.43%; p < 0.0001) and higher rates of heart failure
(2.06% vs 1.62%; p ¼ 0.021) as well as ventricular tachyar-
rhythmias (2.82% vs 2.35%; p ¼ 0.039) than patients with non-
anterior wall MI. Mortality was higher in patients with ante-
rior wall MI (1.85% vs 1.69%; p ¼ 0.395) as compared to the
overall population.
2210 (14.52%) underwent Coronary Angiography; PCI was
done in 1544 (10.14%); and CABG in 253 (1.66%). Hyper-
lipidemics (7.37% vs 4.79%; p < 0.0001) and smokers (5.72% vs
4.79%; p ¼ 0.008) underwent routine PCI following thrombol-
ysis more often than others. The proportion of patients whoTable 2 e Safety of tenecteplase in different subgroups.
Parameter Bleeding
excluding
ICH (%)
Stroke
without
ICH (%)
Total (n ¼ 15,222) 2.01% 0.05%
Females (n ¼ 2561) 1.87% 0.00%
Elderly (n ¼ 1268) 2.99%a 0.08%
DM (n ¼ 6291) 2.18% 0.02%
HT (n ¼ 9366) 2.04% 0.06%
Hyperlipidemia (n ¼ 3584) 2.46% 0.06%
Smokers (n ¼ 5066) 1.74% 0.08%
H/o IHD (n ¼ 2768) 2.35% 0.04%
Patients treated within 3 ha (n ¼ 10,044) 2.08% 0.06%
Patients treated within 3e6 ha (n ¼ 4268) 1.71% 0.02%
Patients treated after 6 ha (n ¼ 903) 2.66% 0.00%
Killip Class III and IV (n ¼ 1446) 2.49% 0.07%
ICH ¼ Intracranial hemorrhage, DM ¼ Diabetes mellitus, HT ¼ Hypertens
Numbers in bold indicate statistical significance.
a Statistically significant.
b Highly significant.underwent coronary artery bypass graft (CABG) was found to
be significantly more in diabetics (2.29% vs 1.66%; p ¼ 0.002)
and hyperlipidemics (2.73% vs 1.66%; p < 0.0001).
The efficacy of TNK in all patients as well those receiving
within 3 h, within 3e6 h and after 6 h is depicted in Fig. 3.
3.4. Safety
Most important safety parameters were taken as an overall
incidence of bleeding (excluding ICH) and the incidence of
non-hemorrhagic stroke and ICH. It was found that incidences
of both these parameters were comparable between the
different subgroups and the overall population. However,
myocardial re-infarction occurred significantly more often in
the elderly group (2.13% vs 1.18%; p ¼ 0.004), hyperlipidemic
patients (1.98% vs 1.18%; p ¼ 0.0002) and in patients receiving
delayed treatment (2.77% vs 1.18%; p < 0.0001) as compared to
the overall population. The incidence of heart failure was
significantly higher in the elderly (3.78%; p < 0.0001), diabeticsICH
(%)
Myocardial
re-infarction
(%)
Heart
failure
(%)
Ventricular
tachyarrhythmia
(%)
0.39% 1.18% 1.62% 2.35%
0.43% 1.13% 1.68% 1.76%
0.87%a 2.13%b 3.78%b 2.92%
0.48% 1.35% 1.95% 2.07%
0.39% 1.14% 1.52% 1.93%
0.42% 1.98%b 3.24%b 3.52%b
0.34% 1.48% 1.76% 2.70%
0.58% 1.63%a 2.49%b 3.29%b
0.33% 0.99% 1.36% 2.06%
0.40% 1.29% 1.69% 2.79%
0.89%a 2.77%b 4.10%b 3.43%b
0.55% 2.42%b 5.88%b 4.56%b
ion, IHD ¼ Ischemic heart disease.
Table 3 e Adverse events according to age group, gender and diabetic status.
Parameter P% in elderly
(>70 year)
(n ¼ 1268)
P% in non-elderly
(70 year)
(n ¼ 13,954)
P% in diabetic
(n ¼ 6291)
P% in non-diabetic
(n ¼ 8931)
P% in males
(n ¼ 12,655)
P% in females
(n ¼ 2561)
Bleeding (excluding ICH) 2.99% 1.92% 2.18% 1.89% 2.04% 1.87%
Any stroke (without ICH) 0.08% 0.04% 0.02% 0.07% 0.05% 0.00%
Any ICH (including those in early
use of GPIIb/IIIa inhibitors)
0.08% 0.06% 0.05% 0.10% 0.08% 0.08%
ICH (not attributable early use
of GPIIb/IIIa inhibitors)
0.63% 0.16% 0.27% 0.17% 0.20% 0.27%
Myocardial re-infraction 2.13% 1.07% 1.35% 1.03% 1.18% 1.13%
Heart failure 3.78% 1.40% 1.95% 1.38% 1.61% 1.68%
Ventricular tachyarrhythmia 2.92% 2.26% 2.07% 2.53% 2.46% 1.76%
Mortality 4.42% 1.41% 2.19% 1.28% 1.44% 2.93%
i n d i a n h e a r t j o u rn a l 6 5 ( 2 0 1 3 ) 4 3 6e4 4 1 439(1.95%; p ¼ 0.088), hyperlipidemics (3.24%; p < 0.0001) and
patients with a history of IHD (2.49%; p ¼ 0.001). Ventricular
tachyarrhythmias occurred significantly more in hyper-
lipidemics (3.52%; p < 0.0001), patients with h/o IHD (3.29%;
p ¼ 0.004) and patients in Killip Classes III & IV (4.56%;
p < 0.0001) than the overall population.
Total mortality in 15,222 patients was found to be 1.69%
(Fig. 2). It was found to be significantly higher in elderly pa-
tients (4.42% vs 1.69%; p < 0.0001), patients receiving delayed
treatment (4.98% vs 1.69%; p < 0.0001) and patients with a
history of IHD (2.67% vs 1.69%; p ¼ 0.0004) as compared to the
general population. Over three fold increase in mortality was
seen in patients receiving delayed treatment. It was also high
in patientswith Killip classes III and IV (5.12%), as compared to
Killip Classes I and II (1.34%; p < 0.0001). In females, mortality
was found to be significantly higher than in male patients
(2.93% vs 1.44%; p < 0.0001).
Very high mortality was reported in patients with failed
thrombolysis (26.74% vs 1.69%; p < 0.0001) as compared to the
overall data. Significantlyhighermortalitywasseen inpatients
with ventricular arrhythmias (7.84%vs 1.69%; p< 0.0001), heart
failure (17.41% vs 1.69%; p < 0.0001) and ICH (23.73% vs 1.69%;
p < 0.0001) as compared to the overall population.Fig. 1 e Clinically successful thrombolysis in different subgroup
Chi square test. DM [ Diabetics, HT [ Hypertension, IHD [ Is4. Discussion
TNK-tPA (tenecteplase) is a bioengineered, third generation
thrombolytic with several advantages which can overcome
the limitations of the previous generation thrombolytic drugs.
TNK scores above its predecessors in terms of efficacy,2
safety2 as well as convenience of use. Various advantages
include better fibrin specificity, fibrin selectivity, faster onset
of action and a longer half life which enables a single bolus
administration as soon as the diagnosis of STEMI is estab-
lished. Both reteplase and alteplase fall short of one ormore of
these parameters. In addition, TNK has a comparatively
higher resistance to plasminogen activator inhibitor-1 (PAI-1)
than both tPA (alteplase) and rPA (reteplase).4 Benefits of TNK
include a reduced mortality in patients receiving delayed
treatment (>4 h) as compared to tPA, so also a comparable
efficacy and lower rate of major bleeding, as documented in
the ASSENT-2 study.5
The current post-marketing observational study has
facilitated the evaluation of TNK in diverse clinical situa-
tions, ranging from a wide demographic profile, co-
morbidities, concurrent medication and huge variation ins. *p< 0.0001, #p [ 0.0004, $p [ 0.006 vs total data using
chemic heart disease.
Fig. 2 e Mortality with tenecteplase amongst different subgroups of patients with STEMI. *p< 0.0001, #p [ 0.012 vs total
data using Chi square test. DM [ Diabetes mellitus, HT [ Hypertensives, IHD [ Ischemic heart disease.
i n d i a n h e a r t j o u r n a l 6 5 ( 2 0 1 3 ) 4 3 6e4 4 1440the time of initiation of treatment. Thus, the efficacy and
safety of TNK have been studied in a plethora of patient
groups, including high risk sub groups, yielding valuable in-
formation on the clinical utility of this third generation
thrombolytic drug.
The results of the present study provide clinical efficacy
and safety of indigenous TNK in over 15,000 Indian patients.
More than 90% clinically successful thrombolysis in the
elderly, diabetics, hypertensives, smokers and hyper-
lipidemics effectively highlights a satisfactory clinical efficacy
of indigenous TNK in routine clinical practice. A lower efficacy
and higher mortality was observed in elderly patients and
patients with a history of IHD. Previous studies have also
documented similar results in these high risk sub groups.5,6
The incidence of ventricular arrhythmias was significantly
more in hyperlipidemics, patients with a history of IHD and
Killip Classes III and IV, while the incidence of myocardial re-
infarction was more in the elderly patients, hyperlipidemics
and in those receiving delayed treatment, as compared to the
overall population. Similarly, the incidence of heart failure
was found to be higher in elderly patients, diabetics, hyper-
lipidemics and patients with a history of IHD. This elucidates
the increased cardiovascular risk associated with these co-
morbidities. In patients receiving TNK >6 h after the onset
of chest pain, the efficacy is reduced which establishes the
importance of timely thrombolysis, consistent with the pre-
vious studies.3,7 Incidence of bleeding (excluding ICH as well
as ICH) and stroke not associated with ICH was comparableFig. 3 e Efficacy of tenecteplase in STEMI patients
(n [ 15,222).amongst all sub groups, thereby emphasizing the safety of
TNK as a fibrinolytic. However, both the safety and efficacy of
TNK were lower in STEMI patients in Killip Classes III and IV,
which is consistent with higher mortality reported in Killip
Classes other than I and II, in spite of Primary PCI.8 It was
observed that female patients of STEMI showed a higher
mortality (2.93%) than the male patients (1.44%) or the total
population (1.69%). This may be attributed to a higher pro-
portion of diabetics (43.54% vs 40.86%) and hypertensives
(63.06% vs 61.18%) in the female sub group, so also to a higher
mean age of females as compared to males. This trend has
been documented earlier by Elaxim registry3 as well as other
published studies,5 further illustrating the fact that even
though the incidence of STEMI is lower in females as
compared to the males, the mortality subsequent to STEMI is
almost twofold higher in females than in males. Another
observation consistent with the findings of the ASSENT-2
study was that patients with an anterior wall MI had a
comparatively poorer outcome as compared to non-anterior
wall MI. The rate of CABG was also found to be higher in
diabetic and hyperlipidemic patients pointing to the fact that
these patients are more likely to have multi-vessel coronary
artery disease.9
The limitation of this study was its observational uncon-
trolled design that depended on reported data. Also, the post
fibrinolytic angiograms were not available for all patients.
None the less, the large sample size allows robust observa-
tions from clinical practice.Fig. 4 e Efficacy of tenecteplase in different patient
subgroups (n [ 15,222).
i n d i a n h e a r t j o u rn a l 6 5 ( 2 0 1 3 ) 4 3 6e4 4 1 4415. Conclusion
The finding of this comprehensive observational study of
15,222 patients in clinical practice conclusively establishes the
safety and efficacy of indigenous TNK-tPA in Indian STEMI
patients, including high-risk sub groups. More importantly,
the study reconfirms the importance of early thrombolysis for
better success rates and clinical outcome, especially in the
Indian scenario where reaching a PCI center may not be
immediately possible. This in turn highlights the value of the
concept of pre-hospital thrombolysis (PHT). Furthermore, the
pharmaco-invasive strategy10,11 of administering thrombo-
lytics followed by a routine PCI may also be an eminently
suitable strategy in the Indian setting, since this study estab-
lishes the efficacy of a thrombolytic like TNK in prompt and
effective reperfusion of the myocardium, which can be fol-
lowed by a routine coronary angiogram at a PCI centre.Conflicts of interest
All authors have none to declare.
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